Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Trastuzumab|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Docetaxel
Sponsor: Centro di Riferimento Oncologico - Aviano